Viyash Scientific Ltd
Viyash Scientific Ltd - 512529 - Announcement under Regulation 30 (LODR)-Updates on Acquisition
01 / The disclosure
What the company shared
Completion of acquisition of BioForLife Italia S.r.l.
A question for your research
Check transaction size, funding, dilution, approvals and completion conditions before assessing the earnings impact.
Numbers found in document text 3 matches
Automatic text matches, not verified financial metrics. A match may come from a table heading or reporting year. Expand it to inspect the surrounding text and original page.
100%Page 1
Pursuant to Regulation 30 of the SEBI Listing Regulations, and in continuation of our earlier disclosures dated June 8, 2026, July 21, 2026, and September 8, 2026 (collectively referred to as the “ Disclosures”) and pursuant to the receipt of necessary approvals, we wish to inform you that Alivira Animal Health Limited, Ireland, a step-down wholly owned subsidiary of Viyash Scientific Limited (“the Company”), has completed the acquisition of 100% of the share capital of BioForLife Italia S.r.l., Milan, Italy (“ BFL Italy”), on October 1, 2026, pursuant to the terms of Sale and Purchase Agreement dated July 21, 2026, executed between BFL Italy and Alivira Animal Health Limited, Ireland (“SPA”).
View source pageEUR 15.0 millionPage 1
The base purchase consideration being paid on the closing is comprising of EUR 15.0 million and the agreed reference net financial position computed as of June 30, 2026 in terms of the SPA.
View source pageEUR 1.976 millionPage 1
The balance purchase consideration of EUR 1.976 million is payable as deferred consideration, subject to necessary adjustments basis the computation of net financial position as on Closing Date (i.e October 1, 2026), in accordance with the SPA.
View source pageThe evidence
Read the source excerpts
01Pursuant to Regulation 30 of the SEBI Listing Regulations, and in continuation of our earlier disclosures dated June 8, 2026, July 21, 2026, and September 8, 2026 (collectively referred to as the “ Disclosures”) and pursuant to the receipt of necessary approvals, we wish to inform you that Alivira Animal Health Limited, Ireland, a step-down wholly owned subsidiary of Viyash Scientific Limited (“the Company”), has completed the acquisition of 100% of the share capital of BioForLife Italia S.r.l., Milan, Italy (“ BFL Italy”), on October 1, 2026, pursuant to the terms of Sale and Purchase Agreement dated July 21, 2026, executed between BFL Italy and Alivira Animal Health Limited, Ireland (“SPA”).
Page 1
02The base purchase consideration being paid on the closing is comprising of EUR 15.0 million and the agreed reference net financial position computed as of June 30, 2026 in terms of the SPA.
Page 1
03The balance purchase consideration of EUR 1.976 million is payable as deferred consideration, subject to necessary adjustments basis the computation of net financial position as on Closing Date (i.e October 1, 2026), in accordance with the SPA.
Page 1
04As part of closing under the SPA, the representatives of Alivira Animal Health Limited, Ireland have been appointed on the Board of BFL Italy.
Page 1
05The Company completed the acquisition in accordance with the terms and conditions previously disclosed.
Page 1
Source & verificationView the disclosure trail
- Summary method
- Exchange-provided text; no generated financial figures
- Exchange identifier
- f888f835-b8b5-453f-9430-63e94e39153c
- First collected
- 3 Oct 2026, 17:18 IST
- PDF extraction
- extracted · 1 pages read
- Extraction note
- Source excerpts; financial tables have not been validated.
- Document SHA-256
- ad46b10b9ecbdc57aa5e59f299d7bf02dc75e7995a3a3e4557231e2f04689848